Department of Genome Biology, Kinki University Faculty of Medicine Osaka, Japan; Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine Kobe, Japan.
Cancer Med. 2013 Apr;2(2):144-54. doi: 10.1002/cam4.68. Epub 2013 Mar 1.
Transcription factor Slug/SNAI2 (snail homolog 2) plays a key role in the induction of the epithelial mesenchymal transition in cancer cells; however, whether the overexpression of Slug mediates the malignant phenotype and alters drug sensitivity in lung cancer cells remains largely unclear. We investigated Slug focusing on its biological function and involvement in drug sensitivity in lung cancer cells. Stable Slug transfectants showed typical morphological changes compared with control cells. Slug overexpression did not change the cellular proliferations; however, migration activity and anchorage-independent growth activity with an antiapoptotic effect were increased. Interestingly, stable Slug overexpression increased drug sensitivity to tubulin-binding agents including vinorelbine, vincristine, and paclitaxel (5.8- to 8.9-fold increase) in several lung cancer cell lines but did not increase sensitivity to agents other than tubulin-binding agents. Real-time RT-PCR (polymerase chain reaction) and western blotting revealed that Slug overexpression downregulated the expression of βIII and βIVa-tubulin, which is considered to be a major factor determining sensitivity to tubulin-binding agents. A luciferase reporter assay confirmed that Slug suppressed the promoter activity of βIVa-tubulin at a transcriptional level. Slug overexpression enhanced tumor growth, whereas Slug overexpression increased drug sensitivity to vinorelbine with the downregulation of βIII and βIV-tubulin in vivo. Immunohistochemistry of Slug with clinical lung cancer samples showed that Slug overexpression tended to be involved in response to tubulin-binding agents. In conclusion, our data indicate that Slug mediates an aggressive phenotype including enhanced migration activity, anoikis suppression, and tumor growth, but increases sensitivity to tubulin-binding agents via the downregulation of βIII and βIVa-tubulin in lung cancer cells.
转录因子 Slug/SNAI2(蜗牛同源物 2)在癌细胞上皮间质转化的诱导中发挥关键作用;然而,Slug 的过表达是否介导肺癌细胞的恶性表型并改变药物敏感性在很大程度上仍不清楚。我们研究了 Slug,重点研究其在肺癌细胞中的生物学功能和对药物敏感性的影响。与对照细胞相比,稳定转染 Slug 的细胞表现出典型的形态变化。Slug 的过表达不会改变细胞增殖;然而,迁移活性和抗凋亡作用的锚定非依赖性生长活性增加。有趣的是,稳定的 Slug 过表达增加了几种肺癌细胞系对微管结合剂(包括长春瑞滨、长春新碱和紫杉醇)的药物敏感性(增加 5.8-8.9 倍),但对微管结合剂以外的药物没有增加敏感性。实时 RT-PCR(聚合酶链反应)和 Western blot 显示,Slug 的过表达下调了βIII 和βIVa-微管蛋白的表达,这被认为是决定对微管结合剂敏感性的主要因素。荧光素酶报告基因测定证实 Slug 在转录水平上抑制了βIVa-微管蛋白的启动子活性。Slug 的过表达增强了肿瘤的生长,而 Slug 的过表达增强了对长春瑞滨的药物敏感性,同时下调了体内βIII 和βIV-微管蛋白的表达。用临床肺癌样本进行 Slug 的免疫组织化学染色显示,Slug 的过表达倾向于参与对微管结合剂的反应。总之,我们的数据表明,Slug 通过下调βIII 和βIVa-微管蛋白介导包括增强的迁移活性、失巢凋亡抑制和肿瘤生长在内的侵袭表型,但增加了对微管结合剂的敏感性。